loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Sharda Cropchem Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Sharda Cropchem Ltd. 30 Oct 2025 15:18 PM
Result PDF

Q2FY26 Quarterly Result Announced for Sharda Cropchem Ltd.

Agrochemicals company Sharda Cropchem announced Q2FY26 results

  • Revenue: Rs 929.1 crore compared to Rs 776.9 crore during Q2FY25, change 20%.
  • EBITDA: Rs 138.9 crore compared to Rs 81.3 crore during Q2FY25, change 71%.
  • EBITDA Margin: 15.0% for Q2FY26.
  • PAT: Rs 74.4 crore compared to Rs 42.4 crore during Q2FY25, change 75%.

Ramprakash Bubna, Chairman & MD, said: “In Q2FY26, we delivered robust revenue growth of 20% YoY to Rs 929 crore, mainly driven by volumes. NAFTA and Europe remains a key contributors in both volume and value terms.

With input costs stabilizing and improving price dynamics, Gross Margins has expanded by 690 basis points to 34.5% and we expect GP Margins to remain in a similar range going ahead. We expect prices to go up going forward. EBITDA has grown by 71% to Rs ~139 crore with EBITDA Margins at 15.0% (improved by 450 bps on Y-o-Y basis). For FY26, we are on track to maintain healthy EBITDA margins in the range of 15–18%.

We remain committed to accelerating product registrations in FY26, supported by a planned capital expenditure of Rs 450–500 crore. Our strong registration pipeline of 1,068 underscores our resilience and sustained growth focus, positioning us well for the long term.”

Result PDF

Result PDF

Agrochemicals company Sharda Cropchem announced Q1FY26 results

  • Revenue: Rs 984.8 crore compared to Rs 785.1 crore during Q1FY25, change 25%.
  • Gross Profit: Rs 349.2 crore compared to Rs 228.9  crore during Q1FY25, change 53%.
  • Gross Profit Margin: 35.5% for Q1FY26.
  • EBITDA: Rs 142.2  crore compared to Rs 85.4 crore during Q1FY25, change 67%.
  • EBITDA Margin: 14.4% for Q1FY26.
  • PAT: Rs 142.8  crore compared to Rs 27.3 crore during Q1FY25, change 424%.

Ramprakash Bubna, Chairman & MD, said: “In Q1FY26, we recorded strong volume growth of ~13%, with revenues rising ~25% YoY to Rs 985 crore. This performance was driven by a global demand revival and improved pricing. Europe remains a key contributor in both volume and value terms.

With input costs stabilizing, our Gross Margins has expanded by 630 basis points to 35.5% and we expect GP Margins to remain in a similar range going ahead. EBITDA has grown by 67% to Rs 142 crore with EBITDA Margins at 14.4%.

We remain focused on increasing our product registrations in FY26, with planned capex of ~Rs 400-450 crore. Our strong pipeline of registrations reflects both our resilience and unwavering commitment to growth, laying a strong foundation for sustained future progress.

For FY26, we aim to grow our topline by ~15% while maintaining healthy EBITDA Margins in the range of 15–18%.”

Result PDF

Agrochemicals company Sharda croreopchem announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue from Operations: Rs 1,828.5 crore in Q4FY25 vs. Rs 1,312.1 crore in Q4FY24 — up 39%
  • Gross Profit: Rs 544.0 crore in Q4FY25 vs. Rs 453.8 crore in Q4FY24 — up 20%
  • Gross Profit Margin: 29.8% in Q4FY25 vs. 34.6% in Q4FY24 — down 480 bps
  • EBITDA: Rs 351.8 crore in Q4FY25 vs. Rs 302.7 crore in Q4FY24 — up 16%
  • EBITDA Margin: 19.2% in Q4FY25 vs. 23.1% in Q4FY24 — down 390 bps
  • PAT: Rs 203.6 crore in Q4FY25 vs. Rs 143.5 crore in Q4FY24 — up 42%

FY25 Financial Highlights:

  • Revenue from Operations: Rs 4,319.9 crore in FY25 vs. Rs 3,163 crore in FY24 — up 37%
  • Gross Profit: Rs 1,291.8 crore in FY25 vs. Rs 820.6 crore in FY24 — up 57%
  • Gross Profit Margin: 29.9% in FY25 vs. 25.9% in FY24 — up 400 bps
  • EBITDA: Rs 681.6 crore in FY25 vs. Rs 318.1 crore in FY24 — up 114%
  • EBITDA Margin: 15.8% in FY25 vs. 10.1% in FY24 — up 570 bps
  • PAT: Rs 304.4 crore in FY25 vs. Rs 31.9 crore in FY24 — up 854%

Commenting on the Results, Ramprakash Bubna, Chairman and MD, said, “During Q4 FY25, the Company has witnessed a revival in demand with Revenues growing by 39% YoY to Rs 1,829 crore despite facing ongoing global challenges and sustained pricing pressures. This resurgence has translated into a strong operational and financial performance in Q4 FY25, reflecting resilience in our business model and the effectiveness of the initiatives taken.

For FY25, Revenues grew by 37% YoY to Rs 4,320 crore. Gross profit margins expanded by 400 basis points to 29.8%, demonstrating our pricing resilience amid global headwinds. EBITDA more than doubled to Rs 682 crore, with EBITDA margins at 15.8%, aligning with our guidance. Agrochemical volumes saw a robust growth of 44% during the year.

With raw material prices stabilising, we expect consistency in gross margins going ahead. Our strong pipeline of registrations reflects both our resilience and unwavering commitment to growth, laying a strong foundation for sustained future progress. We are confident on our ongoing plan to increase product registrations in FY26 with capex guidance of Rs 400-450 crore.

For FY26, we aim to grow our topline by more than 15% while maintaining healthy EBITDA margins in the range of 15–18%.”

Result PDF

Agrochemicals company Sharda Cropchem announced Q3FY25 results

  • Revenue: Rs 929.3 crore compared to Rs 632.5 crore during Q3FY24, change 47%.
  • Gross Profit: Rs 304.2 crore compared to Rs 165.6 crore during Q3FY24, change 84%.
  • Gross Profit Margin: 32.7% for Q3FY25.
  • EBITDA: Rs 156.6 crore compared to Rs 47.2 crore.
  • EBITDA Margin: 16.9% for Q3FY25.
  • PAT: Rs 31.1 crore compared to Rs 4.6 crore during Q3FY24.

Ramprakash Bubna, Chairman and MD, said: “Despite the ongoing global headwinds and persistent pricing pressures, we have seen a revival in demand which has led to a strong performance in Q3FY25

Revenue in Q3FY25 increased by 47%, primarily driven by higher volumes. We saw volume growth across all regions, with Europe, NAFTA and LATAM being key drivers. Agrochemical volumes grew by 49.5% in Q3FY25. With raw material prices stabilising, we have managed to expand the gross margin by 660 bps to 32.7%. We have been working on cost optimization strategies and with operating leverage playing out, we have been able to improve our EBITDA Margins to 16.9% for the quarter.

Our strong pipeline of registrations showcases our resilience and our commitment to growth which establishes a solid foundation for continued progress.

We are confident on our ongoing plan to increase product registrations in FY25 with capex guidance of Rs 400-450 crore enabling us to meet FY25 guidance.”

Result PDF

Agrochemicals company Sharda Cropchem announced Q2FY25 results

Financial Highlights:

  • Revenue: Rs 776.9 crore, compared to Rs 580.8 crore during the period Q2FY24, change 34%.
  • Gross profit: Rs 214.7 crore, compared to Rs 145.5 crore during the period Q2FY24, change 48%.
  • Gross profit Margin: 25.1%.
  • EBITDA: Rs 84.4 crore, compared to Rs 37.7 crore during the period Q2FY24, change 125%.
  • EBITDA margin: 6.5%.
  • PAT: Rs 42.4 crore, compared to Rs -27.6 crore during the period Q2FY24.

Business Highlights:

  • Agrochemical Segment contributes 82%; Non-Agrochemical Segment contributes 18%.
  • Overall Volumes have increased by 20.6% YoY in Q2FY25; Agrochemical volumes grew by 24.6%
  • Agrochemical Segment contributes 84%; Non-Agrochemical Segment contributes 16%.
  • Overall Volumes have increased by 30.3% YoY in H1FY25; Agrochemical volumes grew by 36.0%.
  • Capex in H1FY25 stands at ~Rs. 155 crore.
  • Product Registrations stand at 2,934 with 1,034 applications globally pending at various stages as on 30th September 2024.
  • We remain a debt free company with cash, bank & liquid investments of Rs. 656 crore.

Ramprakash Bubna, Chairman and MD, said: “Despite the global industry challenges, including subdued demand and pricing pressures, we have delivered strong performance in Q2 and H1FY25 compared to last year. Revenue in Q2FY25 increased by 34%, and H1FY25 by 28%, primarily driven by higher volumes and a gradual price increase. We saw volume growth across all regions, with Europe and NAFTA being key contributors. Agrochemical volumes grew by 24.6% in Q2FY25 and by 36.0% in H1FY25. We are optimistic about improving gross margins moving forward.

Our extensive pipeline of registrations showcases our resilience and our commitment to growth. To drive sustainable growth, we intensify our focus on operational efficiencies. This enhances profitability and organizational agility, ensuring a strong foundation for future growth.

We are happy to emphasize our ongoing plan to increase product registrations in FY25 with capex guidance of Rs. 400-450 crore is on track driving revenue growth, improved competitiveness, and increased customer satisfaction.”

Result PDF

Agrochemicals company Sharda Cropchem announced Q1FY25 results:

  • Revenue: Rs 785.1 crore (up 23% YoY)
  • Gross Profit: Rs 228.9 crore (up 311% YoY)
  • Gross Profit Margin (%): 29.2% (up from 8.7% in Q1FY24)
  • EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization): Rs 88.3 crore (from -Rs 66.0 crore in Q1FY24)
  • EBITDA Margin (%): 11.3% (improvement from -10.4% in Q1FY24)
  • PAT (Profit After Tax): Rs 27.3 crore (from -Rs 88.6 crore in Q1FY24)

Commenting on the Results, Ramprakash Bubna, Chairman and MD, said : “In Q1FY25, we recorded an improvement in financial results on YoY basis despite a challenging market environment. Revenue has grown by 23% majorly due to growth in volumes by 41% as compared to last year. We have seen volume growth across all major regions with Europe nearly doubling. Volumes from Agrochemicals grew by 49%. Gross Margins at 29.2% have come back to normalcy and we expect this to improve in this financial year with prices expected to increase. This enhances profitability and organisational agility, ensuring a strong foundation for future growth.

As we look ahead, we aim to increase our product registrations and expect Capex of ~Rs 400-450 crores on the same in FY25 and expand our global presence.” 

Result PDF

Agrochemicals company Sharda Cropchem Announced Q1FY23 Result :

  • Revenue growth led by better price realization and product mix.
  • Gross Margins have been impacted by weakening of €/$ and increase in freight costs
  • EBITDA and Margin impacted due to lower GP Margins and increase in freight costs .
  • PAT was impacted by higher depreciation and forex losses of Rs. Rs. 43.2 cr. in Q1 FY23 vs. Gain of Rs. 11.5 cr. in Q1 FY22 impacting to the tune of Rs. 54.7 Crs.

 

Result PDF

Agrochemicals company Sharda Cropchem declares Q4FY22 result:

  • Revenue growth led by better product mix & price realization
  • Gross Margins were marginally impacted by higher freight costs
  • Growth in EBITDA driven by higher revenues, effective cost management marginally setted off by higher freight cost
  • PBT grew due to better operating leverage. However, it was partly impacted by higher depreciation.
  • PAT grew by 32% to Rs. 177 crores

 

Result PDF

Agrochemicals company Sharda Cropchem declares Q3FY22 result:

  • Revenues grew by 78.2% YoY to Rs 8,798 mn in Q3 FY22 led by strong volume growth across geographies & better product mix & price realization.
  • Gross profit grew by 75% YoY to Rs  2,984 mn in Q3 FY22. Gross margin during Q3 FY22 stood at 33.9%, which is marginally impacted by higher freight costs.
  • EBITDA grew by 97.1% YoY from Rs 1,019 mn in Q3 FY21 to Rs  2,009 mn in Q3 FY22
  • EBITDA margin expanded by 220 bps YoY to 22.8% in Q3 FY22 driven by economies of scale , effective cost management marginally setted off by higher freight cost.
  • PBT grew by 74.9% YoY from Rs 776 mn in Q3 FY21 to Rs 1,358 mn in Q3 FY22 led be better operating leverage, however, it was partly impacted by higher depreciation and forex loss in Q3 FY22 vis-à-vis forex gain in Q3 FY21
  • PAT surged by 111.6% YoY from Rs  483 mn in Q3 FY21 to Rs 1,022 mn in Q3 FY22
  • PAT margin expanded by 184 bps YoY to 11.6% in Q3 FY22 mainly due to lower effective tax rates (24.7% in Q3 FY22 vs. 37.8% in Q3 FY21)
  • Revenues grew by 64.1% YoY to Rs  21,453 mn in 9M FY22 led by strong volume growth across geographies & strong product mix
  • Gross profit grew by 57.8% YoY to Rs  6,608 mn in 9M FY22. Gross margin during 9M FY22 stood at 30.8% , which is marginally impacted by higher freight cost.
  • EBITDA grew by 96.6% YoY from Rs 2,092 mn in 9M FY21 to Rs  4,113 mn in 9M FY22
  • EBITDA margin expanded by 317 bps YoY to 19.2 % in 9M FY22 driven by economies of scale & effective cost management, which is marginally impacted by higher freight costs.
  • PBT grew by 71.0% YoY from Rs 1,425 mn in 9M FY21 to Rs  2,438 mn in 9M FY22 led by better operating leverage, partly impacted by higher depreciation & forex loss in 9M FY22 vs forex gain in 9M FY21
  • PAT surged by 80.8% YoY from Rs 953 mn in 9M FY21 to Rs 1,723 mn in 9M FY22
  • PAT margin expanded by 74 bps YoY to 8.0 % in 9M FY22 mainly due to lower effective tax rates (29.3% in 9M FY22 vs. 33.1% in 9M FY21)

 

Result PDF

Highlights

  • Revenues grew by 51.3% YoY to Rs 6,428 mn in Q2 FY22 led by strong volume growth across geographies
  • Gross profit grew by 36.3% YoY to Rs 1,798 mn in Q2 FY22. Gross margin during Q2 FY22 stood at 28.0%
  • EBITDA grew by 76.8% YoY from Rs 587 mn in Q2 FY21 to Rs 1,038 mn in Q2 FY22
  • EBITDA margin expanded by 233bps YoY to 16.1% in Q2 FY22 driven by volume growth and better cost management, partly impacted by change in product mix and inflation in the freight cost.
  • PBT grew by 37.3% YoY from Rs302 mn in Q2 FY21 to Rs 415 mn in Q2 FY22, partly impacted by higher depreciation charge and forex loss in Q2 FY22 vis-àvis forex gain in Q2 FY21
  • PAT surged by 67.9% YoY from Rs 191 mn in Q2 FY21 to Rs 320 mn in Q2 FY22
  • PAT margin expanded by 49bps YoY to 5.0% in Q2 FY22 mainly due to lower effective tax rates (22.9% in Q2 FY22 vs. 36.9% in Q2 FY21)
  • Revenues grew by 55.5% YoY to Rs 12,655 mn in H1 FY22 led by strong volume growth across geographies
  • Gross profit grew by 46.0% YoY to Rs 3,624 mn in H1 FY22. Gross margin during H1 FY22 stood at 28.6%
  • EBITDA grew by 96.1% YoY from Rs 1,073 mn in H1 FY21 to Rs 2,104 mn in H1 FY22
  • EBITDA margin expanded by 344bps YoY to 16.6% in H1 FY22 driven by volume growth and better cost management, partly impacted by change in the product mix and inflation in the freight cost.
  • PBT grew by 66.3% YoY from Rs 649 mn in H1 FY21 to Rs 1,080 mn in H1 FY22 led by better operating leverage ,partly impacted higher depreciation & forex loss in H1FY22 vs forex gain in FY21.
  • PAT surged by 49.2% YoY from Rs470 mn in H1 FY21 to Rs 701 mn in H1 FY22
  • PAT margin contracted by 24bps YoY to 5.5% in H1 FY22 mainly due to higher effective tax rates (35.1% in H1 FY22 vs. 27.6% in H1 FY21)

Result PDF

Trending News

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

Published on 18-Dec-2025 09:07

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Published on 18-Dec-2025 09:06

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

Published on 18-Dec-2025 09:05

L&T's Buildings & Factories (B&F) business has won multiple large domestic EPC orders across tourism

L&T's Buildings & Factories (B&F) business has won multiple large domestic EPC orders across tourism

Published on 18-Dec-2025 09:03

Marico has amended the definitive agreements to extend the timeline for acquiring the remaining 40% stake in Satiya Nutraceuticals (PLIX) by 12 months

Marico has amended the definitive agreements to extend the timeline for acquiring the remaining 40% stake in Satiya Nutraceuticals (PLIX) by 12 months

Published on 18-Dec-2025 09:01

Axis Bank MD & CEO Amitabh Chaudhry said that recent RBI rate cuts will delay stabilisation of net interest margins

Axis Bank MD & CEO Amitabh Chaudhry said that recent RBI rate cuts will delay stabilisation of net interest margins

Published on 18-Dec-2025 09:00

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status